Company

 

 

 

Aug 2010 05

Salient Surgical Technologies Reaches Corporate Purchasing Agreement with HealthTrust Purchasing Group, L.P.

(Portsmouth, NH) In a move that signals growing mainstream acceptance of its proprietary TRANSCOLLATION™ technology, Salient Surgical Technologies, Inc. announced today that it has reached a corporate purchasing agreement with HealthTrust Purchasing Group, L.P. (HealthTrust). The multi-year contract began on August 1, 2010.

HealthTrust's membership supports nearly 1,400 not-for-profit and for-profit acute care facilities, as well as ambulatory surgery centers, physician practices, and alternate care sites.

The corporate agreement provides a standardized process for the utilization of Salient products within HealthTrust’s network of affiliated health-care centers.

“This is an important agreement for Salient,” said Joseph F. Army, President and CEO of Salient Surgical Technologies. “HealthTrust’s commitment to superior patient care by outfitting their hospitals with up-to-date technology fits perfectly with our mission of improving patient outcomes while lowering the costs of medical care.”

About HealthTrust Purchasing Group
HealthTrust Purchasing Group, headquartered in Brentwood, Tenn., is a group purchasing organization that supports nearly 1,400 not-for-profit and for-profit acute care facilities, as well as ambulatory surgery centers, physician practices, and alternate care sites. With an annual purchasing volume by its members of more than $17 billion, HealthTrust is committed to obtaining the best price for clinically-recommended products, ensuring their timely delivery and continuously evaluating and improving its services to the patients, physicians and clinicians it serves. HealthTrust is located at 155 Franklin Road, Suite 400, Brentwood, TN 37027. The Web site is www.healthtrustpg.com.

About Salient Surgical Technologies
Salient Surgical Technologies, Inc. (www.salientsurgical.com) is a medical technology company that develops and markets advanced energy devices for use in surgical procedures. Salient's proprietary TRANSCOLLATION™ technology provides hemostatic sealing of soft tissue, bone and vessels. This allows surgeons to rapidly treat tissue at the surgical site to reduce blood loss and improve patient outcomes. Salient's products are currently used in orthopedic reconstruction, spine surgery, trauma procedures and surgical oncology. To date, TRANSCOLLATION™ technology has been used in over 450,000 surgical procedures.

Contact:
Richard Altieri, CFO
Salient Surgical Technologies, Inc.
603-742-1515
raltieri@salientsurgical.com
 

 

Jun 2010 17

Salient Opens European Headquarters to Support Expansion Efforts

Targeting of Orthopedic Reconstruction and Spine Procedures to Power Growth in Established Markets

(Portsmouth, NH) – Salient Surgical Technologies, Inc. has opened an office in Amsterdam, the Netherlands to support its global expansion efforts. Salient first entered the European market in 2001 with its line of monopolar sealers for use in solid organ resections. Clinical results in total joint replacement and spine procedures with the AQUAMANTYS® System, a bipolar technology, have led to rapid growth and a renewed focus on expanding the company’s presence in international markets.

Combined, the five largest markets in Europe (UK, Germany, France, Italy and Spain) perform over one million orthopedic reconstruction procedures annually.

“TRANSCOLLATION™ technology is a natural fit for all healthcare systems that seek to improve outcomes and lower costs,” said Salient president and CEO Joseph F. Army in a statement. “Our goal is to make the AQUAMANTYS® System the global standard of care for reducing the clinical and economic burdens associated with bleeding and blood loss during surgical procedures.”

The new European office will house Salient’s international sales and marketing team.

About Salient Surgical Technologies
Salient Surgical Technologies, Inc. is a medical technology company that develops and markets advanced energy devices for use in surgical procedures. Salient's proprietary TRANSCOLLATION technology delivers concurrent radiofrequency energy and saline for haemostatic sealing of soft tissue and bone at the operative site. Salient's products are currently used in orthopedic reconstruction and trauma, spine surgery and surgical oncology. To date, TRANSCOLLATION technology has been used in over 400,000 surgical procedures.

International Contact:
Boudewijn Bollen
VP, International Sales
Salient Surgical Cooperatief U.A.
+31 (0)36 767 0300

 

 

Jun 2010 11

Salient Sues Bovie Medical for Patent Infringement

(PORTSMOUTH, NH) Salient Surgical Technologies, Inc., a privately held medical technology company that develops and markets advanced energy devices for use in surgical procedures, announced that Tuesday they filed a lawsuit in the U.S. District Court for the District of Delaware against Bovie® Medical (Amex: BVX) for patent infringement. The complaint charges that Bovie's manufacture, use, and sale of the SEER (Saline Enhanced Electrosurgical Resection) device infringes U.S. Patent No. 7,364,579, titled "Fluid-assisted Electrosurgical Device" (the '579 Patent). Salient has licensed the '579 Patent from Medtronic Corporation, which is also a plaintiff in the case.

About Salient Surgical Technologies
Salient Surgical Technologies, Inc. (www.salientsurgical.com) is a medical technology company that develops and markets advanced energy devices for use in surgical procedures. Salient's proprietary TRANSCOLLATION® technology allows surgeons to rapidly treat tissue at the surgical site by transforming specific types of collagen-based structures to improve patient outcomes. Salient's products are currently used in orthopedic reconstruction and trauma, reconstruction, spine surgery and surgical oncology. To date, TRANSCOLLATION technology has been used in over 400,000 surgical procedures.

Contact:
Richard Altieri
CFO, Salient Surgical Technologies
(603) 742-1515
richard.altieri@salientsurgical.com
 

 

Jun 2010 07

Salient Surgical Technologies Expands Presence in Japanese Market with AQUAMANTYS® System

Japanese Government Awards Ninsho Pre-market Certification to AQUAMANTYS System

(Portsmouth NH) Salient Surgical Technologies announced today that the Japanese government has awarded Ninsho Pre-market Certification for the company’s AQUAMANTYS® System, clearing it for sale in Japan.

The AQUAMANTYS System employs Salient’s proprietary TRANSCOLLATION™ technology, a combination of radiofrequency energy and saline for haemostatic sealing of soft tissue and bone designed to improve patient outcomes and lower costs for hospitals in a wide variety of surgical procedures.

Salient won Ninsho certification for the AQUAMANTYS System as part of a year-long process in partnership with its Japanese distributor Century Medical, Inc. (CMI), a subsidiary of the ITOCHU Corporation.

 “For over eight years, Century Medical has helped us succeed in bringing innovative technologies to the Japanese market,” Salient President & CEO Joseph F. Army said in a statement. “Certification of the AQUAMANTYS System will enable our partners at CMI to help surgeons across an expanding range of specialties to improve outcomes for their patients and achieve new efficiencies in their delivery of medical care.”

CMI has hired and trained a special sales force dedicated solely to supporting the AQUAMANTYS System’s introduction to the Japanese market.

About Salient Surgical Technologies
Salient Surgical Technologies, Inc. is a medical technology company that develops and markets advanced energy devices for use in surgical procedures. Salient's proprietary TRANSCOLLATION technology allows surgeons to rapidly treat tissue at the surgical site by transforming specific types of collagen-based structures to improve patient outcomes. Salient's products are currently used in orthopedic reconstruction and trauma, spine surgery and surgical oncology. To date, TRANSCOLLATION technology has been used in over 400,000 surgical procedures.

USA Contact:
Richard Altieri
CFO, Salient Surgical Technologies
(603) 742-1515
raltieri@salientsurgical.com

Japan Contact:
Century Medical, Inc.
+81-3-3491-0165
###

 

 

Apr 2010 14

Orthopedic Trauma Launch

Benefits of TRANSCOLLATION™ technology brought to pelvic fracture, hip and acetabulum fracture, amputation, osteotomy and debridement procedures

(Portsmouth NH) As part of its continuing efforts to improve patient outcomes and reduce non-routine discharges for its hospital customers, Salient Surgical Technologies, Inc. today announced the availability of its line of AQUAMANTYS® bipolar sealers for use in orthopedic trauma procedures.

Already in wide use for spinal fusion and orthopedic reconstruction of the hip and knee, the AQUAMANTYS System can help the surgeon achieve hemostasis quickly while avoiding damage to delicate structures. Typical applications include lower limb amputation, pelvic osteotomy, and large debridement procedures; sacral, hip, periprosthetic and femoral fractures and long bone non-union procedures.

The AQUAMANTYS System employs TRANSCOLLATION technology, Salient’s proprietary combination of radiofrequency energy and saline that seals specific types of collagen based tissues while maintaining temperatures at or below one-hundred degrees Celsius.

“Our customers tell us that the two things that matter most for good patient outcomes in orthopedic trauma cases are a good reduction and gentle tissue management,” said Joseph F. Army, President and Chief Executive Officer of Salient. “The AQUAMANTYS System’s ability to deliver gentle, low-temperature hemostasis makes this entry into trauma procedures a natural progression in the expanding adoption of TRANSCOLLATION technology.”

About Salient Surgical Technologies
Salient Surgical Technologies, Inc. is a medical technology company that develops and markets advanced energy devices for use in surgical procedures. Salient's proprietary TRANSCOLLATION ™ technology allows surgeons to rapidly treat tissue at the surgical site by transforming specific types of collagen based structures to improve patient outcomes. Salient's products are currently used in orthopedic reconstruction, spine and surgical oncology. To date, TRANSCOLLATION ™ technology has been used in over 400,000 surgical procedures.

 

Jan 2010 29

Haiti Donation

Portsmouth, NH, January 29, 2010 – Salient Surgical Technologies of Portsmouth, New Hampshire, has partnered with Exeter Hospital in Exeter, New Hampshire and Moffitt Cancer Center in Tampa, Florida, to donate equipment and supplies for a mission to aid victims of the January 12 earthquake in Haiti. The mission, led by Dr. Harvey Montijo of the Center for Bone and Joint Surgery in Royal Palm Beach, FL, will provide free care for Haitians who have suffered traumatic bone fractures and other injuries.

Salient donated two of its AQUAMANTYS™ electrosurgical generators, 300 AQUAMANTYS bipolar sealers and several boxes of assorted surgical supplies. Exeter Hospital and Moffitt Cancer Center each donated a supply of sterile saline, which the AQUAMANTYS System’s TRANSCOLLATION™ technology requires to operate.

Salient’s TRANSCOLLATION technology and the AQUAMANTYS System are helpful in controlling bleeding and blood loss in the types of traumatic bone fractures Dr. Montijo says he has encountered in his medical missions to Haiti.

Salient, which has a new in-house manufacturing capability, stepped up production of its popular line of AQUAMANTYS bipolar sealers to accommodate the donation.

“We typically keep only a small amount of saline on hand for product demonstrations, so we did not have enough to meet the needs of the large number of surgeries Dr. Montijo will perform during his upcoming mission,” said Joseph F. Army, President and Chief Executive Officer of Salient. “But when we went to our friends at Exeter Hospital and Moffitt Cancer Center for assistance, they were more than willing to pull from their own stores and help make our donation possible.”

About Salient Surgical Technologies
Salient Surgical Technologies, Inc. is a medical technology company that develops and markets advanced energy devices for use in surgical procedures. Salient's proprietary TRANSCOLLATION ™ technology allows surgeons to rapidly treat tissue at the surgical site by transforming specific types of collagen based structures to improve patient outcomes. Salient's products are currently used in orthopedic reconstruction, spine and surgical oncology. To date, TRANSCOLLATION ™ technology has been used in over 375,000 surgical procedures.

 

Jan 2010 29

New Financing Round

Capital Will Be Used To Fund Company Growth and Expansion Plans

Portsmouth, NH, January 25, 2010 – Salient Surgical Technologies, Inc., a privately held medical technology company that develops and markets advanced energy devices for use in surgical procedures, today announced the completion of its Series G financing totaling $15.1 million. Investors in the round included Apothecary Capital/BBT Fund, L.P., Arnerich Massena & Associates, Affinity Capital, Medtronic, Inc., and other financial and strategic investors.

Salient will use the proceeds to expand its sales and marketing organization, build upon its health outcomes data and accelerate development of new advanced energy products based on its proprietary TRANSCOLLATION™ technology.

“We are pleased to welcome new investors Apothecary and Affinity, and thank our returning investors for their continued support. We made excellent progress in 2009 and this financing will provide the capital to fund our global expansion and product pipeline on our way to becoming Standard of Care.” stated Joseph F. Army, President and CEO of Salient.

“Apothecary Capital on behalf of the BBT Fund is excited to have the opportunity to invest in Salient Surgical. We look forward to supporting Salient’s compelling technology and its bright future.” stated Alan Sebulsky, Apothecary’s Managing Partner.

About Salient Surgical Technologies
Salient Surgical Technologies, Inc. is a medical technology company that develops and markets advanced energy devices for use in surgical procedures. Salient's proprietary TRANSCOLLATION technology allows surgeons to rapidly treat tissue at the surgical site by transforming specific types of collagen based structures to improve patient outcomes.  Salient's products are currently used in orthopedic reconstruction, spine and surgical oncology. To date, TRANSCOLLATION technology has been used in over 375,000 surgical procedures.

 

Mar 2009 03

New Epidural Vein Sealer

(Portsmouth, NH) As part of its ongoing effort to improve patient outcomes for spinal procedures and reduce non-routine patient discharges for its hospital customers, Salient Surgical Technologies, Inc. today unveiled the AQUAMANTYS™ Epidural Vein Sealer (EVS) bipolar device at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in Las Vegas, NV.

The EVS is designed to address the challenging anatomy in minimally invasive spine surgery and is the latest product introduction on Salient’s proprietary AQUAMANTYS platform. The EVS employs TRANSCOLLATION™ advanced energy technology to significantly reduce bleeding in hard-to-reach areas. Reducing blood loss improves visualization for the surgeon, can result in improved clinical outcomes for the patient and may result in lower costs to the hospital.

TRANSCOLLATION technology is a calibrated fusion of radiofrequency energy and saline that gently seals bleeding tissues, vessels and bone at the surgical site. The innovation of the EVS is the ability to deliver TRANSCOLLATION technology through miniaturized electrodes, which provide direct and precise compression of epidural veins around critical structures. The EVS is used with the same AQUAMANTYS System Generator as Salient’s standard 2.3 and 6.0 Bipolar Sealer devices.

“Our substantially increased investment in research and development has begun to yield results with the launch of the EVS at AAOS. We are delighted to offer this expansion of our product,” said Joe Army, CEO of Salient Surgical Technologies. “The EVS represents the latest in a series of innovations designed to improve patient outcomes and reduce hospital costs that we have planned for 2009.”

Salient Surgical Technologies, Inc. is a medical technology company that develops and markets innovative tools designed to improve patient outcomes and reduce the cost of medical care. The Company’s proprietary TRANSCOLLATION technology is designed to deliver economic value to hospitals and simplify surgery by providing surgeons the ability to significantly reduce blood loss in a broad range of procedures. Salient’s AQUAMANTYS System uses TRANSCOLLATION technology to help surgeons improve patient outcomes for orthopedic reconstruction, spinal fusion and solid organ resection procedures. To date, TRANSCOLLATION technology has been used in over 250,000 surgical procedures.

 

 

Dec 2008 29

New Corporate Headquarters

New Construction Includes Training, Manufacturing Facilities

Portsmouth, NH – Salient Surgical Technologies, Inc., a privately held medical technology company that develops and markets advanced energy devices for use in surgical procedures, today announced the completion of its new corporate headquarters in Portsmouth, New Hampshire at the Pease International Tradeport. The 56,658 square foot facility was built to suit by Two International Group.

“This new facility provides exciting opportunities for our continued growth,” stated Joseph F. Army, Salient’s President & CEO. “It brings many new capabilities to our corporate office, including a specially-equipped training facility and a pilot line to support our increased investments in new product development.”

About Salient Surgical

Salient Surgical Technologies, Inc. is a medical technology company that develops and markets advanced energy devices for use in surgical procedures. Salient's proprietary TRANSCOLLATION™ technology allows surgeons to provide optimized tissue treatment at the surgical site by transforming specific types of collagen-based structures to improve patient outcomes. Salient's products are currently used in orthopedic reconstruction, spine and surgical oncology. To date, TRANSCOLLATION technology has been used in over 200,000 surgical procedures.